orabase and Asthma

orabase has been researched along with Asthma* in 2 studies

Other Studies

2 other study(ies) available for orabase and Asthma

ArticleYear
Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma.
    Drug design, development and therapy, 2015, Volume: 9

    The purpose of the present study was to develop oral dispersible tablets containing prednisolone (PDS)-loaded chitosan nanoparticles using microcrystalline cellulose (MCC 101), lactose, and croscarmellose sodium (CCS). The PDS-loaded chitosan nanoparticles were formulated by ionotropic external gelation technique in order to enhance the solubility of PDS in salivary pH. Prepared nanoparticles were used for the development of oral fast disintegrating tablets by direct compression method. The prepared tablets were evaluated for disintegration time (DT), in vitro drug release (DR), thickness, weight variation, drug content uniformity, friability, and hardness. The effect of concentrations of the dependent variables (MCC, lactose, CCS) on DT and in vitro DR was studied. Fast disintegrating tablets of PDS can be prepared by using MCC, CCS, and lactose with enhanced solubility of PDS. The minimum DT was found to be 15 seconds, and the maximum DR within 30 minutes was 98.50%. All independent variables selected for the study were statistically significant. Oral fast disintegrating tablets containing PDS nanoparticles could be the better choice for the pediatric patients that would result in better patient compliance. From this study, it can be concluded that fast disintegrating tablets could be a potential drug delivery technology for the management of asthma in pediatrics.

    Topics: Administration, Oral; Anti-Inflammatory Agents; Asthma; Carboxymethylcellulose Sodium; Cellulose; Chemistry, Pharmaceutical; Chitosan; Drug Delivery Systems; Drug Liberation; Excipients; Hardness; Humans; Hydrogen-Ion Concentration; Lactose; Nanoparticles; Prednisolone; Solubility; Tablets

2015
In vitro and in vivo evaluation of buccal bioadhesive films containing salbutamol sulphate.
    Chemical & pharmaceutical bulletin, 2010, Volume: 58, Issue:3

    The aim of present study was to prepare and evaluate buccal bioadhesive films of salbutamol sulphate (SS) for the treatment of asthma. The films were designed to release the drug for a prolonged period of time so as to reduce the frequency of administration of the available conventional dosage forms of SS. The different proportions of sodium carboxymethylcellulose (SCMC) and Carbopol 940P (CP 940P) were used for the preparation of films. Carbopol was used to incorporate the desired bioadhesiveness in the films. The films were prepared by solvent casting method and evaluated for bioadhesion, in vitro drug release and anti asthmatic effect (bronchoprotection) in histamine induced bronchospasm of guinea pigs. In vitro drug release from the film was determined using a modified Franz diffusion cell while bioadhesiveness was evaluated with a modified two-arm balance using guinea pig buccal mucosa as a model tissue. Films containing SCMC : CP 940P ratio of 76 : 24 was found to be the best with moderate swelling along with favorable bioadhesion force and in vitro drug release. The drug release mechanism was found to follow non-Fickian diffusion as release mechanism. The prolonged in vivo effect (bronchoprotection) obtained from the buccal bioadhesive film of SS administered via buccal route may improve the treatment of asthmatic disorders by reducing the frequency of administration which is associated with the tolerance effect of SS. Additionally for the clinical benefit, it is also expected to reduce the major adverse effects of SS such as tachycardia and arrhythmias via buccal absorption.

    Topics: Acrylic Resins; Adhesiveness; Administration, Buccal; Albuterol; Animals; Anti-Asthmatic Agents; Asthma; Biological Availability; Carboxymethylcellulose Sodium; Chemistry, Pharmaceutical; Diffusion; Drug Design; Guinea Pigs; Solubility

2010